AU2013356934C1 - Glucagon/GLP-1 agonists for the treatment of obesity - Google Patents

Glucagon/GLP-1 agonists for the treatment of obesity Download PDF

Info

Publication number
AU2013356934C1
AU2013356934C1 AU2013356934A AU2013356934A AU2013356934C1 AU 2013356934 C1 AU2013356934 C1 AU 2013356934C1 AU 2013356934 A AU2013356934 A AU 2013356934A AU 2013356934 A AU2013356934 A AU 2013356934A AU 2013356934 C1 AU2013356934 C1 AU 2013356934C1
Authority
AU
Australia
Prior art keywords
ser
xaa
arg
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013356934A
Other languages
English (en)
Other versions
AU2013356934A1 (en
AU2013356934B2 (en
Inventor
Balaji AGORAM
Madeleine ANTONSSON
Maria Bednarek
Lambertus BENTHEM
Nicole BURMEISTER
David FAIRMAN
Maria FRITSCH-FREDIN
Ronald Jackson
Rasmus Jansson Lofmark
Jacqueline METCALFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2013356934A1 publication Critical patent/AU2013356934A1/en
Publication of AU2013356934B2 publication Critical patent/AU2013356934B2/en
Priority to AU2017261505A priority Critical patent/AU2017261505C1/en
Application granted granted Critical
Publication of AU2013356934C1 publication Critical patent/AU2013356934C1/en
Priority to AU2019272054A priority patent/AU2019272054A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2013356934A 2012-12-11 2013-12-10 Glucagon/GLP-1 agonists for the treatment of obesity Ceased AU2013356934C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017261505A AU2017261505C1 (en) 2012-12-11 2017-11-15 Glucagon/glp-1 agonists for the treatment of obesity
AU2019272054A AU2019272054A1 (en) 2012-12-11 2019-11-29 Glucagon/glp-1 agonists for the treatment of obesity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11
US61/735,823 2012-12-11
PCT/IB2013/003191 WO2014091316A2 (en) 2012-12-11 2013-12-10 Glucagon/glp-1 agonists for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017261505A Division AU2017261505C1 (en) 2012-12-11 2017-11-15 Glucagon/glp-1 agonists for the treatment of obesity

Publications (3)

Publication Number Publication Date
AU2013356934A1 AU2013356934A1 (en) 2015-05-21
AU2013356934B2 AU2013356934B2 (en) 2017-08-17
AU2013356934C1 true AU2013356934C1 (en) 2018-07-05

Family

ID=50588751

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013356934A Ceased AU2013356934C1 (en) 2012-12-11 2013-12-10 Glucagon/GLP-1 agonists for the treatment of obesity
AU2017261505A Ceased AU2017261505C1 (en) 2012-12-11 2017-11-15 Glucagon/glp-1 agonists for the treatment of obesity
AU2019272054A Abandoned AU2019272054A1 (en) 2012-12-11 2019-11-29 Glucagon/glp-1 agonists for the treatment of obesity

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017261505A Ceased AU2017261505C1 (en) 2012-12-11 2017-11-15 Glucagon/glp-1 agonists for the treatment of obesity
AU2019272054A Abandoned AU2019272054A1 (en) 2012-12-11 2019-11-29 Glucagon/glp-1 agonists for the treatment of obesity

Country Status (26)

Country Link
US (4) US9765130B2 (https=)
EP (2) EP3495380B1 (https=)
JP (1) JP6490011B2 (https=)
KR (1) KR102080366B1 (https=)
CN (2) CN104822699B (https=)
AR (1) AR093903A1 (https=)
AU (3) AU2013356934C1 (https=)
BR (1) BR112015012238B1 (https=)
CA (1) CA2893445C (https=)
CY (2) CY1121114T1 (https=)
DK (2) DK3495380T3 (https=)
ES (2) ES2926713T3 (https=)
HR (2) HRP20220734T1 (https=)
HU (1) HUE039952T2 (https=)
LT (2) LT2931745T (https=)
MX (2) MX365458B (https=)
PL (2) PL3495380T3 (https=)
PT (2) PT2931745T (https=)
RS (2) RS63305B1 (https=)
RU (2) RU2671088C2 (https=)
SG (2) SG10201801159WA (https=)
SI (2) SI3495380T1 (https=)
SM (2) SMT201800611T1 (https=)
TR (1) TR201815172T4 (https=)
TW (2) TWI617574B (https=)
WO (1) WO2014091316A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CA2902352A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh) * 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN113456820B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
ES2983409T3 (es) * 2016-03-10 2024-10-23 Medimmune Ltd Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
US20190388510A1 (en) * 2016-06-02 2019-12-26 Indiana University Research And Technology Corporation Glucagon-t3 conjugates
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
MX2020010505A (es) 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
EP3882263A4 (en) * 2018-11-12 2022-08-31 Tianjin Institute Of Pharmaceutical Research Co., Ltd. GLUCAGON DERIVED PEPTIDE AND USE THEREOF
CA3139613A1 (en) 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EA202290107A1 (ru) 2019-07-01 2022-03-29 Медиммун Лимитед Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
JP2023505126A (ja) * 2019-12-03 2023-02-08 メディミューン，エルエルシー 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
KR20230005289A (ko) 2020-04-24 2023-01-09 베링거 인겔하임 인터내셔날 게엠베하 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
US20240148833A1 (en) * 2022-11-03 2024-05-09 EFIL BioScience Inc. Composition comprising glp-1 receptor agonist and acat inhibitor
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
WO2025024788A1 (en) * 2023-07-27 2025-01-30 Biomedit, Llc Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof
CN118787658B (zh) * 2024-06-14 2025-01-21 中国农业大学 一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用
WO2026058194A1 (en) 2024-09-12 2026-03-19 Medimmune Limited Polypeptide dosage regimens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp－1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
MX2010004298A (es) * 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
MX2012013001A (es) * 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Glucagon analog peptide sequence, SEQ ID 524.", DATABASE Geneseq, Database accession no. AZP67221, URL: EBI, * sequence . * *

Also Published As

Publication number Publication date
CN104822699A (zh) 2015-08-05
MX2019006260A (es) 2019-08-14
PL3495380T3 (pl) 2022-08-01
WO2014091316A2 (en) 2014-06-19
RU2018137842A (ru) 2018-12-13
EP2931745A2 (en) 2015-10-21
CY1125302T1 (el) 2025-03-28
PT2931745T (pt) 2018-11-29
CA2893445C (en) 2020-06-02
SI2931745T1 (sl) 2018-11-30
RU2015127780A (ru) 2017-01-19
AU2019272054A1 (en) 2020-01-02
RS63305B1 (sr) 2022-07-29
AR093903A1 (es) 2015-06-24
PL2931745T3 (pl) 2019-04-30
TWI617574B (zh) 2018-03-11
AU2017261505A1 (en) 2017-12-07
WO2014091316A3 (en) 2014-10-30
KR102080366B1 (ko) 2020-02-21
CN104822699B (zh) 2019-03-01
SI3495380T1 (sl) 2022-08-31
LT2931745T (lt) 2018-11-12
LT3495380T (lt) 2022-06-27
PT3495380T (pt) 2022-06-28
MX388904B (es) 2025-03-20
SG11201503230XA (en) 2015-06-29
RU2671088C2 (ru) 2018-10-29
TW201829452A (zh) 2018-08-16
AU2013356934A1 (en) 2015-05-21
EP2931745B1 (en) 2018-08-22
DK3495380T3 (da) 2022-06-20
RS57899B1 (sr) 2019-01-31
JP2016501256A (ja) 2016-01-18
SMT201800611T1 (it) 2019-01-11
EP3495380B1 (en) 2022-03-30
BR112015012238B1 (pt) 2022-03-29
AU2013356934B2 (en) 2017-08-17
US11230584B2 (en) 2022-01-25
US20200115431A1 (en) 2020-04-16
RU2018137842A3 (https=) 2022-04-01
HRP20220734T1 (hr) 2022-09-02
CA2893445A1 (en) 2014-06-19
HUE039952T2 (hu) 2019-02-28
TW201427993A (zh) 2014-07-16
MX2015006568A (es) 2015-08-05
US20220098265A1 (en) 2022-03-31
JP6490011B2 (ja) 2019-03-27
HK1216179A1 (en) 2016-10-21
MX365458B (es) 2019-06-04
TWI674270B (zh) 2019-10-11
CN109776670A (zh) 2019-05-21
KR20150093167A (ko) 2015-08-17
US10556939B2 (en) 2020-02-11
DK2931745T3 (en) 2018-12-10
SG10201801159WA (en) 2018-03-28
ES2926713T3 (es) 2022-10-27
ES2698329T3 (es) 2019-02-04
TR201815172T4 (tr) 2018-11-21
BR112015012238A2 (https=) 2017-08-15
AU2017261505B2 (en) 2019-10-10
US20150307579A1 (en) 2015-10-29
SMT202200266T1 (it) 2022-07-21
US9765130B2 (en) 2017-09-19
CY1121114T1 (el) 2019-12-11
US20170342121A1 (en) 2017-11-30
EP3495380A1 (en) 2019-06-12
AU2017261505C1 (en) 2020-07-30
HRP20181678T1 (hr) 2019-03-08

Similar Documents

Publication Publication Date Title
AU2013356934C1 (en) Glucagon/GLP-1 agonists for the treatment of obesity
US9714277B2 (en) Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
KR102460198B1 (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
HK40010017B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK40010017A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK1216179B (en) Glucagon/glp-1 agonists for the treatment of obesity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 MAR 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 MAR 2018

MK14 Patent ceased section 143(a) (annual fees not paid) or expired